

## Special Issue

# Advances in Diagnosis and Therapeutic Strategies for Uveal Melanoma

### Message from the Guest Editor

Uveal melanoma is a highly aggressive malignancy, often resistant to radiation and systemic therapies. Recent advances have brought significant progress in treating metastatic uveal melanoma, with FDA-approved therapies such as tebentafusp, darovasertib, and HEPZATO KIT. These therapies have shown improved overall response rates and patient survival compared to standard treatments. However, challenges remain. For instance, tebentafusp improves overall survival but achieves measurable tumor shrinkage in only 5–11% of patients. This underscores the need to enhance therapeutic efficacy and expand benefits to more patients. Meanwhile, emerging insights into the genetic and immune landscapes of uveal melanoma open new avenues for developing novel, more effective treatment strategies. Furthermore, the implementation of new therapies has underscored the importance of optimizing treatment management and addressing emerging challenges, including therapy-associated side effects. For this Special Issue, we invite authors to contribute papers exploring innovations in translational drug discovery, and advancements in the diagnosis and clinical management of uveal melanoma.

### Guest Editor

Dr. Yong Qin

Department of Pharmaceutical Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA

### Deadline for manuscript submissions

31 August 2025



## Journal of Clinical Medicine

an Open Access Journal  
by MDPI

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/225733](https://mdpi.com/si/225733)

*Journal of Clinical Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jcm@mdpi.com](mailto:jcm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jcm](https://jcm)





# Journal of Clinical Medicine

---

an Open Access Journal  
by MDPI

---

Impact Factor 2.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
jcm](https://mdpi.com/journal/jcm)



## About the Journal

### Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

---

### Editors-in-Chief

Prof. Dr. Emmanuel Andr  s

Internal Medicine Department, University Hospital Strasbourg, 67000  
Strasbourg, France

Prof. Dr. Kent Doi

Department of Acute Care Medicine, University of Tokyo, Tokyo, Japan

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.7 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the first half of 2025).